Inhibition of ERβ induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wilk, Anna ^a   Waligorska, Agnieszka ^a   Waligorski, Piotr ^a   Ochoa, Augusto ^a   Reiss, Krzysztof ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; ESTROGEN RECEPTOR BETA; FULVESTRANT; RAD51 PROTEIN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTRADIOL; RAD51 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER RESISTANCE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GLIOMA CELL; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL; PROTEIN PHOSPHORYLATION; RECOMBINATION REPAIR; DNA REPAIR; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; HUMANS; MEDULLOBLASTOMA; RAD51 RECOMBINASE; RNA, SMALL INTERFERING;

EID: 84858419862     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033867     Document Type: Article

References (50)

1. Yates AJ, Becker LE, Sachs LA, (1979) Brain tumors in childhood. Childs Brain 5: 31-39.
2. Reiss K, (2002) Insulin-like growth factor-I receptor- a potential therapeutic target in medulloblastomas. Expert Opin Ther Targets 6: 539-544.
3. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A, (2008) Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14: 971-976.
4. McComb JG, Davis RL, Isaacs H Jr, (1981) Extraneural metastatic medulloblastoma during childhood. Neurosurgery 9: 548-551.
5. Katsetos CD, Burger PC, (1994) Medulloblastoma. Semin Diagn Pathol 11: 85-97.
6. Katsetos CD, Del Valle L, Legido A, de Chadarevian JP, Perentes E, et al. (2003) On the neuronal/neuroblastic nature of medulloblastomas: a tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol 105: 1-13.
7. Ikeda Y, Nagai A, (2006) Differential expression of the estrogen receptors alpha and beta during postnatal development of the rat cerebellum. Brain Res 1083: 39-49.
8. Belcher SM, Ma X, Le HH, (2009) Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology 150: 1112-1121.
9. Urbanska K, Pannizzo P, Lassak A, Gualco E, Surmacz E, et al. (2009) Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma. J Cell Physiol 219: 392-401.
10. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, et al. (2009) Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis 24: 613-622.
11. Lau KM, LaSpina M, Long J, Ho SM, (2000) Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60: 3175-3182.
12. Ricke WA, Wang Y, Cunha GR, (2007) Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 75: 871-882.
13. Speirs V, (2008) The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res 10: 111.
14. Wurster M, Ruoff A, Meisner C, Seeger H, Vogel U, et al. (2010) Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer. Oncol Rep 24: 653-659.
15. Bergner CC, Krause FS, Zugor V, Rith T, Schrott KM, et al. (2007) Polymorphisms of human estrogen receptor (ER) gene alpha and beta in prostate cancer PC-EW and PC-OR cell lines. Anticancer Res 27: 2071-2074.
16. Leung YK, Gao Y, Lau KM, Zhang X, Ho SM, (2006) ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia 8: 242-249.
17. Fox EM, Davis RJ, Shupnik MA, (2008) ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73: 1039-1051.
18. Ercoli A, Battaglia A, Raspaglio G, Fattorossi A, Alimonti A, et al. (2000) Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction. Int J Cancer 85: 98-103.
19. Garcia-Lopez P, Rodriguez-Dorantes M, Perez-Cardenas E, Cerbon M, Mohar-Betancourt A, (2004) Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines. Cancer Chemother Pharmacol 53: 533-540.
20. Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, et al. (2002) Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 71: 249-255.
21. Koberle B, Tomicic MT, Usanova S, Kaina B, (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806: 172-182.
22. Smith J, Tho LM, Xu N, Gillespie DA, (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108: 73-112.
23. Brozovic A, Damrot J, Tsaryk R, Helbig L, Nikolova T, et al. (2009) Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. Mutat Res 670: 32-41.
24. Wozniak K, Blasiak J, (2002) Recognition and repair of DNA-cisplatin adducts. Acta Biochim Pol 49: 583-596.
25. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, et al. (2003) Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 142: 178-186.
26. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC, (2008) Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 28: 337-344.
27. Britten RA, Kuny S, Perdue S, (1999) Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. Br J Cancer 79: 843-849.
28. Huang X, Okafuji M, Traganos F, Luther E, Holden E, et al. (2004) Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 58A: 99-110.
29. Trojanek J, Ho T, Croul S, Wang JY, Chintapalli J, et al. (2006) IRS-1-Rad51 nuclear interaction sensitizes JCV T-antigen positive medulloblastoma cells to genotoxic treatment. Int J Cancer 119: 539-548.
30. Frankenberg-Schwager M, Kirchermeier D, Greif G, Baer K, Becker M, et al. (2005) Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 212: 175-184.
31. Trojanek J, Croul S, Ho T, Wang JY, Darbinyan A, et al. (2006) T-antigen of the human polyomavirus JC attenuates faithful DNA repair by forcing nuclear interaction between IRS-1 and Rad51. J Cell Physiol 206: 35-46.
32. Collins AR, Oscoz AA, Brunborg G, Gaivao I, Giovannelli L, et al. (2008) The comet assay: topical issues. Mutagenesis 23: 143-151.
33. Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, et al. (2003) Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 23: 7510-7524.
34. Schmutte C, Tombline G, Rhiem K, Sadoff MM, Schmutzler R, et al. (1999) Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH). Cancer Res 59: 4564-4569.
35. Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R, (2005) Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314: 495-505.
36. Reiss K, Khalili K, Giordano A, Trojanek J, (2006) JC virus large T-antigen and IGF-I signaling system merge to affect DNA repair and genomic integrity. J Cell Physiol 206: 295-300.
37. Pierce AJ, Johnson RD, Thompson LH, Jasin M, (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13: 2633-2638.
38. Hoeijmakers JH, (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
39. Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER, (2009) Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair. Mol Biol Cell 20: 3374-3389.
40. Sisci D, Morelli C, Cascio S, Lanzino M, Garofalo C, et al. (2007) The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann Oncol 18 (Suppl 6): vi81-85.
41. Robertson JF, (2001) Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol 79: 209-212.
42. de Vincenzo R, Scambia G, Benedetti Panici P, Bonanno G, Ercoli A, et al. (1996) Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells. Ann N Y Acad Sci 784: 517-520.
43. Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, et al. (2004) Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol 130: 405-410.
44. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, et al. (1998) Differential expression of estrogen receptor-alpha and-beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58: 5367-5373.
45. Stefanou D, Batistatou A, Briasoulis E, Arkoumani E, Agnantis NJ, (2004) Estrogen receptor beta (ERbeta) expression in breast carcinomas is not correlated with estrogen receptor alpha (ERalpha) and prognosis: the Greek experience. Eur J Gynaecol Oncol 25: 457-461.
46. Batistatou A, Kyzas PA, Goussia A, Arkoumani E, Voulgaris S, et al. (2006) Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol 77: 17-23.
47. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D, (2006) Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 5: 1539-1549.
48. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, et al. (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766: 63-78.
49. He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, et al. (1991) Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Invest 64: 833-843.
50. Urbanska K, Pannizzo P, Grabacka M, Croul S, Del Valle L, et al. (2008) Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int J Cancer 123: 1015-1024.